SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CNSI Cambridge Neuroscience
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: dalroi who wrote (574)5/8/2000 5:15:00 PM
From: Cheryl Galt  Read Replies (1) of 675
 
Mike and Stefaan -- " peripheral neuropathy can be very severe AND is not exlusively linked to cisplatinum ... "

Add thalidomide to the list. Neuropathy is a major treatment limiting side effect.
-------------

IMO, any drug that limits neuropathy will also be welcomed by type 2 diabetics -- most of whom (even those who are well controlled) likely have some degree of it. Neuropathy is more than a pain; it has serious health consequence, even for diabetics unaware they have this problem. A drug that limited neuropathy would likely become part of routine diabetes care.

I've never bought a lottery ticket, but I've got some CNSI.
With its science, credible partners, financial stability
-- IMO CNSI is cheap enough to keep some tucked away.

Heck. Its price is no more than one of my mis-calculations
-- the "delta" of one of my slightly high entry points for more expensive stocks.

I soon forget such deltas. So I'm forgetting the price of this development-stage, under-the-radar company
-- and enjoying all the reminders you guys provide of its nifty projects.

Regards,
Cheryl

PS -- I sure wish I could see what's going on with them and Allergan. I suspect that will be fruitful in due time.
Has anyone noticed anything from that quarter?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News